EAN 2022 | Personalized B-cell tailored dosing of ocrelizumab in MS

Alyssa Toorop, MD, PhD, Amsterdam University Medical Center, Amsterdam, The Netherlands, discusses work evaluating personalized dosing of ocrelizumab in patients with multiple sclerosis (MS). During the COVID-19 pandemic, extended interval dosing of ocrelizumab was studied in patients with low B-cell count, and results showed a low short-term incidence of disease activity. Currently, the multicenter randomized BLOOMS trial (NCT05296161) is evaluating the efficacy, safety, and cost-effectiveness of ocrelizumab when administered in personalized B-cell tailored intervals in relapsing-remitting multiple sclerosis (RRMS) patients. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.